Free Trial

PureTech Health (LON:PRTC) Stock Price Up 14.2% - What's Next?

PureTech Health logo with Medical background

Key Points

  • PureTech Health's stock price surged 14.2%, closing at GBX 121.50 ($1.64) after trading as high as GBX 123.80 ($1.67) on a volume increase of 1,053% compared to its average daily trading volume.
  • Corporate insider Bharatt Chowrira purchased 167,739 shares at an average cost of GBX 1 per share, signifying confidence in the company's prospects.
  • The company, which focuses on developing medicines for various health issues, has a market capitalization of £293.65 million with a high price-to-earnings ratio of 714.71.
  • Five stocks we like better than PureTech Health.

PureTech Health plc (LON:PRTC - Get Free Report) shares shot up 14.2% during mid-day trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares traded hands during trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Up 14.2%

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The company has a market capitalization of £293.65 million, a P/E ratio of 714.71 and a beta of 1.02. The stock has a 50-day moving average price of GBX 129.46 and a 200-day moving average price of GBX 129.72.

Insider Buying and Selling

In other news, insider Bharatt Chowrira acquired 167,739 shares of PureTech Health stock in a transaction on Thursday, July 3rd. The stock was purchased at an average price of GBX 1 per share, with a total value of £1,677.39. Company insiders own 13.13% of the company's stock.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Featured Stories

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.